Esperion Therapeutics (NASDAQ:ESPR) vs. Gain Therapeutics (NASDAQ:GANX) Head-To-Head Review

Esperion Therapeutics (NASDAQ:ESPR) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.

Valuation & Earnings

This table compares Esperion Therapeutics and Gain Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Esperion Therapeutics	$403.14 million	2.00	-$22.68 million	($0.06)	-52.17
Gain Therapeutics	$50,000.00	1,663.35	-$20.16 million	($0.58)	-3.36

Gain Therapeutics has lower revenue, but higher earnings than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Esperion Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500.

Institutional and Insider Ownership

47.4% of Esperion Therapeutics shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 1.6% of Esperion Therapeutics shares are owned by insiders. Comparatively, 4.2% of Gain Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Esperion Therapeutics and Gain Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Esperion Therapeutics	1	6	1	0	2.00
Gain Therapeutics	1	0	5	0	2.67

Esperion Therapeutics currently has a consensus target price of $5.54, indicating a potential upside of 77.00%. Gain Therapeutics has a consensus target price of $8.50, indicating a potential upside of 335.90%. Given Gain Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Gain Therapeutics is more favorable than Esperion Therapeutics.

Profitability

This table compares Esperion Therapeutics and Gain Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Esperion Therapeutics	0.12%	-0.14%	0.12%
Gain Therapeutics	N/A	-201.44%	-136.24%

About Esperion Therapeutics

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company’s products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

About Gain Therapeutics

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.